Search research articles
Contact Us
Filters
Showing results (641-650 of 701) with videos related to
Page
of 71
Sort By:
American Journal of Obstetrics and Gynecology
|
May 15, 2019
A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome
Beryl L Manning-Geist, Katherine Hicks-Courant, Allison A Gockley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 27, 2013
Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer
Jose Alejandro Rauh-Hain, Stephanie H Guseh, Katharine M Esselen, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 26, 2025
Evidence for ApoE receptor 2-Disabled homolog-1 pathway disruption in the amygdala in sporadic Alzheimer's disease
Christopher E Ramsden, Mark S Horowitz, Daisy Zamora, et al.
Gynecologic Oncology
|
June 24, 2018
Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
Beryl L Manning-Geist, Katherine Hicks-Courant, Allison A Gockley, et al.
Gynecologic Oncology
|
July 10, 2021
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer
Carolyn N Krasner, Susana M Campos, Chantay L Young, et al.
Annals of Surgical Oncology
|
March 8, 2021
Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer
Beryl L Manning-Geist, Mackenzie W Sullivan, Vishnudas Sarda, et al.
Clinics (Sao Paulo, Brazil)
|
July 31, 2023
Immunotherapy in the treatment of chemoresistant gestational trophoblastic neoplasia - systematic review with a presentation of the first 4 Brazilian cases
Antonio Braga, Elaine Balthar, Laís Cristhine Santos Souza, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 2, 2013
Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto's) thyroiditis: a randomized controlled clinical trial
Lowell R Schmeltz, Thomas C Blevins, Stephen L Aronoff, et al.
Gynecologic Oncology
|
March 13, 2019
Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
Paulo Alexandre Ribeiro Mora, Sue Yazaki Sun, Guillermo Coca Velarde, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
November 12, 2016
Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA
Jaclyn C Watkins, Brooke E Howitt, Neil S Horowitz, et al.
Page
of 71
Search research articles
Search
Showing results (641-650 of 701) with videos related to
Sort By:
Page
of 71
American Journal of Obstetrics and Gynecology
|
May 15, 2019
A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome
Beryl L Manning-Geist, Katherine Hicks-Courant, Allison A Gockley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 27, 2013
Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer
Jose Alejandro Rauh-Hain, Stephanie H Guseh, Katharine M Esselen, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 26, 2025
Evidence for ApoE receptor 2-Disabled homolog-1 pathway disruption in the amygdala in sporadic Alzheimer's disease
Christopher E Ramsden, Mark S Horowitz, Daisy Zamora, et al.
Gynecologic Oncology
|
June 24, 2018
Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
Beryl L Manning-Geist, Katherine Hicks-Courant, Allison A Gockley, et al.
Gynecologic Oncology
|
July 10, 2021
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer
Carolyn N Krasner, Susana M Campos, Chantay L Young, et al.
Annals of Surgical Oncology
|
March 8, 2021
Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer
Beryl L Manning-Geist, Mackenzie W Sullivan, Vishnudas Sarda, et al.
Clinics (Sao Paulo, Brazil)
|
July 31, 2023
Immunotherapy in the treatment of chemoresistant gestational trophoblastic neoplasia - systematic review with a presentation of the first 4 Brazilian cases
Antonio Braga, Elaine Balthar, Laís Cristhine Santos Souza, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 2, 2013
Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto's) thyroiditis: a randomized controlled clinical trial
Lowell R Schmeltz, Thomas C Blevins, Stephen L Aronoff, et al.
Gynecologic Oncology
|
March 13, 2019
Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
Paulo Alexandre Ribeiro Mora, Sue Yazaki Sun, Guillermo Coca Velarde, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
November 12, 2016
Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA
Jaclyn C Watkins, Brooke E Howitt, Neil S Horowitz, et al.
Page
of 71